(Q37813126)

23 August 2017

1 reference

title

Alternative therapies for Clostridium difficile infections (English)

1 reference

23 August 2017

Clostridium difficile

0 references

Jack Brown

4

0 references

Elizabeth Dodds Ashley

series ordinal

3

object named as

Elizabeth Dodds Ashley

1 reference

23 August 2017

Charles Venuto

1

1 reference

PubMed ID

21114394

23 August 2017

Mary Butler

series ordinal

2

1 reference

PubMed ID

21114394

23 August 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

23 August 2017

1 reference

23 August 2017

30

1 reference

23 August 2017

12

1 reference

23 August 2017

1266-1278

1 reference

Clostridium difficile-associated disease: changing epidemiology and implications for management

23 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Emergence of Clostridium difficile-associated disease in North America and Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

High frequency of antibiotic-associated diarrhea due to toxin A-negative, toxin B-positive Clostridium difficile in a hospital in Japan and risk factors for infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Risk factors for vancomycin-resistant Enterococcus (VRE) infection in colonized patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Clinical practice. Antibiotic-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Clostridium difficile--more difficult than ever

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Risk factors for Clostridium difficile toxin-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Recurrent Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Regulatory effects of bifidobacteria on the growth of other colonic bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Inhibition of Clostridium difficile growth and adhesion to enterocytes by Bifidobacterium supernatants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Nitazoxanide for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Nitazoxanide: a new thiazolide antiparasitic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Treatment with monoclonal antibodies against Clostridium difficile toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Lactobacillus and bifidobacteria combinations: a strategy to reduce hospital-acquired Clostridium difficile diarrhea incidence and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Variation in human intestinal microbiota with age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Outbreak of Saccharomyces cerevisiae Subtype boulardii Fungemia in Patients Neighboring Those Treated with a Probiotic Preparation of the Organism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Lactobacillus acidophilus bacteraemia after use of a probiotic in a patient with AIDS and Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.12.1266

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.12.1266

1 reference

23 August 2017

1 reference

PubMed ID

21114394